Nothing Special   »   [go: up one dir, main page]

WO2000047196A3 - Use of statins for treating viral infections - Google Patents

Use of statins for treating viral infections Download PDF

Info

Publication number
WO2000047196A3
WO2000047196A3 PCT/US2000/003634 US0003634W WO0047196A3 WO 2000047196 A3 WO2000047196 A3 WO 2000047196A3 US 0003634 W US0003634 W US 0003634W WO 0047196 A3 WO0047196 A3 WO 0047196A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
statin
viral infections
viral
statins
Prior art date
Application number
PCT/US2000/003634
Other languages
French (fr)
Other versions
WO2000047196A2 (en
Inventor
Patrick T Prendergast
Original Assignee
Hollis Eden Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollis Eden Pharmaceuticals filed Critical Hollis Eden Pharmaceuticals
Priority to CA002363088A priority Critical patent/CA2363088A1/en
Priority to JP2000598149A priority patent/JP2002536405A/en
Priority to AU29917/00A priority patent/AU2991700A/en
Priority to EP00908609A priority patent/EP1150665A2/en
Publication of WO2000047196A2 publication Critical patent/WO2000047196A2/en
Publication of WO2000047196A3 publication Critical patent/WO2000047196A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods of treating a vertebrate, particularly a mammal and more particularly murine or human patient, suffering from one or more viral infections, or a cell line infected with one or more viral infections, said viral infections including but not limited to the infections of the following viruses: hepatitis C, HIV, hepatitis A, hepatitis B, hepatitis G, or hepatitis H, by administering to said patient infected with at least one of virus at least one statin or statin-like compound determined to have anti-viral activity according to the present invention, said anti-viral statin or statin-like compound being selected from the group consisting of: mevastatin, lovastatin, pravastatin, simvastatin, and the compounds disclosed in U.S. Patents Nos. 4,346,227, 4,448,979, 4,739,073, 5,273,995, 5,169,857, 5,006,530, and 5,401,746.
PCT/US2000/003634 1999-02-11 2000-02-11 Use of statins for treating viral infections WO2000047196A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002363088A CA2363088A1 (en) 1999-02-11 2000-02-11 Methods for treating viral infections
JP2000598149A JP2002536405A (en) 1999-02-11 2000-02-11 How to treat viral infections
AU29917/00A AU2991700A (en) 1999-02-11 2000-02-11 Methods for treating viral infections
EP00908609A EP1150665A2 (en) 1999-02-11 2000-02-11 Use of statins for treating viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11962999P 1999-02-11 1999-02-11
US60/119,629 1999-02-11

Publications (2)

Publication Number Publication Date
WO2000047196A2 WO2000047196A2 (en) 2000-08-17
WO2000047196A3 true WO2000047196A3 (en) 2001-03-15

Family

ID=22385429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003634 WO2000047196A2 (en) 1999-02-11 2000-02-11 Use of statins for treating viral infections

Country Status (6)

Country Link
EP (1) EP1150665A2 (en)
JP (1) JP2002536405A (en)
AU (1) AU2991700A (en)
CA (1) CA2363088A1 (en)
WO (1) WO2000047196A2 (en)
ZA (1) ZA200106406B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531799A1 (en) * 2002-06-10 2005-05-25 Elan Pharma International Limited Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
WO2004096194A2 (en) * 2003-04-30 2004-11-11 Consejo Superior De Investigaciones Cientificas Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
US8765704B1 (en) * 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
WO2006039656A2 (en) * 2004-10-01 2006-04-13 Novartis Vaccines And Diagnostics Inc. Modified small interfering rna molecules and methods of use
EP1658845A1 (en) * 2004-10-06 2006-05-24 PrimaGen Holding B.V. Use of statin or precursor thereof for the treatment of virusinfections
WO2006038797A1 (en) * 2004-10-06 2006-04-13 Primagen Holding B.V. Use of statin or precursor thereof for the treatment of hiv infections
US20090318379A1 (en) * 2006-05-04 2009-12-24 Prendergast Patrick T Statins for the Treatment of Viral Influenza Infections
KR20100005063A (en) * 2006-09-18 2010-01-13 패트릭 티. 프렌더게스트 Compositions comprising a statin and caffeine for the treatment of viral infection
EP2241561A1 (en) * 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
FR3041529A1 (en) * 2015-09-24 2017-03-31 Inst De Rech Pour Le Dev (Ird) COMPOSITIONS USEFUL FOR THE TREATMENT OF ARBOVIROSES
KR102581090B1 (en) * 2020-10-16 2023-09-21 고려대학교 세종산학협력단 Pharmaceutical composition for the treatment of porcine epidemic diarrhea virus comprising statin compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058505A2 (en) * 1998-05-12 1999-11-18 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635114T2 (en) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. PROTEIN FUNGAL SYN-TRANSFERASE INHIBITORS IN COMBINATION WITH HMGCOA REDUCTASE INHIBITORS FOR THE TREATMENT OF AIDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058505A2 (en) * 1998-05-12 1999-11-18 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAZIERE J C ET AL: "LOVASTATIN INHIBITS HIV-1 EXPRESSION IN H9 HUMAN T LYMPHOCYTES CULTURED IN CHOLESTEROL-POOR MEDIUM", BIOMEDICINE AND PHARMACOTHERAPY,ELSEVIER, PARIS,FR, vol. 48, no. 2, 1994, pages 63 - 67, XP000965739 *
See also references of EP1150665A2 *

Also Published As

Publication number Publication date
EP1150665A2 (en) 2001-11-07
AU2991700A (en) 2000-08-29
CA2363088A1 (en) 2000-08-17
WO2000047196A2 (en) 2000-08-17
JP2002536405A (en) 2002-10-29
ZA200106406B (en) 2003-02-03

Similar Documents

Publication Publication Date Title
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
WO2000047196A3 (en) Use of statins for treating viral infections
CA2221370A1 (en) Composition for treating condyloma acuminata
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
ID27787A (en) COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
CA2268709A1 (en) Hiv protease inhibitors
BR9913935A (en) Methods of treatment and prevention of infection caused by at least one virus of the family of flaviviridae and disease associated with said infection in a living host
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
WO2001090121A3 (en) Methods and compositions for treating hepatitis c virus
RU98112594A (en) TREATING A HIV-CENTERED CENTRAL NERVOUS SYSTEM BY VX-478, ISOLATED EITHER IN COMBINATION WITH AZT OR ZTS
DK0930885T3 (en) The use of heparin or heparan sulfate in combination with chitosan for the prevention or treatment of herpes virus infections
ES2123048T3 (en) ANTIVIRIC NUCLEOSID ANALOGS.
CA2218561A1 (en) Compounds and methods of use to treat infectious diseases
ZA991029B (en) Composition and methods for treatment of hiv infections.
AU7677891A (en) Inhibition of disease associated with immunodeficiency virus infection
GEP20084377B (en) Agent for inhibiting membrane virus reproduction, method for the production thereof, pharmaceutical composition and method for inhibiting viral infections
AU3530293A (en) Compositions for the treatment of infection and disease caused by hepatitis B virus (HBV)
WO2003053332A3 (en) Composition and method for treating viral infection
ATE152717T1 (en) NAPHTOQUINONE COMPOUNDS, COMPOSITIONS AND USES ACTIVE AGAINST VIRUSES
WO2001010454A3 (en) Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
CA2281133A1 (en) Multiple-agents-binding compound and use thereof
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
WO1993014760A3 (en) Methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 29917/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000908609

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/06406

Country of ref document: ZA

Ref document number: 200106406

Country of ref document: ZA

ENP Entry into the national phase

Ref country code: CA

Ref document number: 2363088

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598149

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000908609

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2363088

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000908609

Country of ref document: EP